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Abstract
In this paper, for time-to-event data, we propose a new statistical framework for casual infer-
ence in evaluating clinical utility of predictive biomarkers and in selecting an optimal treatment
for a particular patient. This new casual framework is based on a new concept, called Biomarker
Adjusted Treatment Effect (BATE) curve, which can be used to represent the clinical utility
of a predictive biomarker and select an optimal treatment for one particular patient. We then
propose semi-parametric methods for estimating the BATE curves of biomarkers and establish
asymptotic results of the proposed estimators for the BATE curves. We also conduct exten-
sive simulation studies to evaluate finite-sample properties of the proposed estimation methods.
Finally, we illustrate the application of the proposed method in a real-world data set.
Keywords: Predictive biomarker; cutoff points; interaction; BATE curve; time-to-event outcome;
varying-coefficient.
1. INTRODUCTION
Due to complexity of cancer, current staging and risk-stratification methods in oncology, while
helpful, often fail to adequately predict malignancy aggressiveness and/or response to a specific
treatment. The rapid advance of molecular genetic technology and accompanying proliferation of
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molecular diagnostics companies have set the stage for a new era in personalized medicine. This
development allows the tumor-node-metastasis (TNM) staging system to incorporate additional
biomarkers, such as gene expression data, which could provide more precise information for risk
stratification and treatment selection. By identifying patients who are at high risk and who are
more likely to benefit from a given treatment, we hope to be able to provide the most effective
treatment to those who are most in need.
A predictive marker is a biomarker that predicts the differential efficacy (benefit) of a par-
ticular therapy based on the value of a biomarker (e.g., only patients expressing the biomarker
will respond to the specific treatment or will respond to a greater degree than those without the
biomarker) (Sargent 2005). To apply these exciting results to maximize patient benefit, we need to
develop a systematic statistical methodology to assess the clinical utility of promising biomarkers
for predicting patients’ responses to particular treatments.
Most of the current statistical methods for assessing the clinical utility of a predictive biomarker
are based on a comparison of estimated survival curves between a treatment and control group,
stratified by the biomarker values. Such an approach has two main limitations. First, if the
biomarker yields a continuous-scale, such the approach requires dichotomization, which is artificial
and may lose important information. Second, such the approach does not adequately quantify the
clinical utility of predictive biomarkers. Specifically, many biomarkers that may have a significant
p-value but do not have true clinical utility. Statistical significance does not imply clinical relevance.
Other two methods for assessing clinical utility of predictive biomarkers have been also proposed
in the literature (Freidlin and Simon, 2005; Jiang, 2007). Freidlin and Simon (2005) proposed a
design that combines prospective development of a gene expression-based classifier to select sensitive
patients with a properly powered test for overall effect, by assuming the biomarker is binary. Jiang
et al. (2007) extended Freidlin’s design to allow a continuous-scale biomarker and proposed a
parametric model to select a cut point for a pre-specified biomarker of the sensitive subpopulation.
Both these methods have limitations. The first drawback is the strong assumption that the effect
of the interaction between the biomarker and the treatment group on patient outcomes is a step-
function with only one jump of the biomarker value. However, when the biomarker is continuous,
it’s most likely that the interaction continuously varies with the value of the biomarker. Another
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main drawback of Jiang’s method is that the proposed model with a unknown cut point is not
identifiable. One additional limitation of all above mentioned existing methods is that they are not
based on a causal framework.
In this paper, for a randomized clinical trial with full compliance, we propose a new statis-
tical framework for casual inference in assessing the effectiveness of predictive biomarkers and in
selecting sensitive patients to one particular treatment. Our new statistical framework overcomes
the limitations of the existing methods for evaluating predictive biomarkers in selecting optimal
treatments for individual patients. Specifically, in this paper, we introduce a new concept, called
the Biomarker Adjusted Treatment Effect (BATE) curve, which is a graphical plot of the treatment
effect as a function of the biomarker value and can be used to select an optimal treatment for an
individual patient. Compared to the existing methods, the BATE curve can visually display the
treatment effect on the patient’s outcome as a function of the biomarker value.
This article is organized as follows. In Sections 2 and 3, we illustrate the mathematic definitions
and applications of our proposed BATE curves to select cutoff points, compare biomarkers, choose
the optimal treatment for individual patients for the situation with multiple treatments, and test
the usefulness of a predictive biomarker, In Section 4, we propose an estimation method for BATE
curves and derive asymptotic properties of the estimated BATE curves. In Section 5, we derive
the asymptotic distribution of the maximum deviations of the estimated BATE curves from the
true BATE curves, and use it to construct the test statistics for the null hypothesis that the BATE
curve is a constant and to construct simultaneous confidence bands for the BATE curve. Simulation
studies and a real data example are reported in Sections 6 and 7, respectively. We give detailed
proofs of the asymptotic results in Appendix C.
2. THE BATE CURVE FOR A TWO-ARM RANDOMIZED CLINICAL TRIALS WITH
FULL COMPLIANCE
As discussed above, it is reasonable to assume that the treatment effect is a continuous curve of the
biomarker value. This curve, which is named as the Biomarker Adjusted Treatment Effect (BATE)
curve, is also flexible enough to indicate both local and global association between treatment and
the biomarker value. In this section, for the randomized clinical trial with full compliance and with
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one experimental and one control arms, we define the BATE curve mathematically for time-to-
event outcome based on a casual framework, and demonstrate its detailed applications, such as the
selection of sensitive patients and the identification of cutoff points. We then extend the BATE
curve to the randomized clinical trial with full compliance and with multiple treatment arms in
Section 3.
We first give some necessary notation and definitions.
2.1 Notation
Suppose that n independent subjects are randomized over experimental treatment or control. We
let Ti(1) be the event time of a subject that would be observed if the ith subject had received
the experimental arm and Ti(0) be the event time that would be observed if the ith subject had
received the control arm. For one single biomarker V , we further define two potential conditional
hazard rate functions as follows:
λ(1)(t|v) = lim
∆t→0
P (t < Ti(1) ≤ t+∆t|Ti(1) > t, Vi = v)
∆t
,
λ(0)(t|v) = lim
∆t→0
P (t < Ti(0) ≤ t+∆t|Ti(0) > t, Vi = v)
∆t
.
Let Ti denote the event time, and we let Ci denote the censoring time and let Xi = min(Ti, Ci)
denote the observed time for the ith individual, i = 1, · · · , n. Let ∆i be an indicator which equals
1 if Xi is an event time and 0 otherwise. Let Vi and Zi denote the biomarker value and treatment
group indicator for the ith individual, respectively, where Zi = 1 if individual i is assigned to the
experimental group and Zi = 0 otherwise, i = 1, · · · , n. We assume that the censoring times are
independent of the failure times conditional on the covariates and that the observation period is
[0, τ ], where τ is a constant denoting the time for end of the study.
2.2 The BATE Curve
To evaluate the treatment effect adjusted for one single continuous biomarker V , we assume that the
multiplicative interaction is of interest, we define the biomarker-adjusted treatment effect (BATE)
curve at time t as follows:
β(v; t) = log
{
λ(1)(t|v)
λ(0)(t|v)
}
. (1)
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Here β(v; t) is an unknown smooth function of v for any fixed t ∈ (0, τ).
In a randomized clinical trial with full compliance, since λ(1)(t|v) = λ(t|Z = 1, V = v) and
λ(0)(t|v) = λ(t|Z = 0, V = v), we can express the BATE curve as
β(v; t) = log
{
λ(t|Z = 1, V = v)
λ(t|Z = 0, V = v)
}
. (2)
In this paper, we focus on a special case that β(v; t) ≡ β(v). This assumption holds under
many well known models, such as Cox’s model and varying-coefficient Cox’s model. To get our
idea across, hence we assume the observed data follow the following varying-coefficient proportional
hazard regression model:
λ(t|Zi, Vi) = λ0(t) exp{β(Vi)Zi + g(Vi)}, (3)
where β(·), an unknown smooth function, is the BATE curve, and g(·) is an unknown smooth
function. Here λ(t|Zi, Vi) is the conditional hazard function of the observed event time T , given Zi
and Vi. Next we give a detailed discussion on the use of the BATE curve β(v).
First, the BATE curve β(·) can be used graphically to identify a subset of patients who will not
benefit or even may be harmed by the new treatment, and define the cutoff points based on different
clinical significant levels in order to identify sensitive patients for the new treatment. For example,
a monotonically increasing BATE curve implies that patients with lower biomarker levels are more
likely benefited from the new therapy, see Figure 1(A). In Figure 1, we let α = − log(8) ≈ −2.08,
which means that the risk of the event for patients in the control group is eight times as large as
the risk in the experimental group. Without loss of generality, we also assume that the range of the
biomarker is [0,1]. In this situation, the constant cα such that β(cα) = α, will be the standard cutoff
point, and patients with the biomarker levels falling into [0, cα] should be the sensitive patients.
Conversely, a monotonically decreasing BATE curve implies that patients with higher biomarker
levels are more likely benefited from the new therapy, see Figure 1(B). We choose the cutoff point,
cα, such that β(cα) = α, and patients with the biomarker levels in [cα, 1] should be the sensitive
patients. For a non-monotonically BATE curve, such as the one in Figure 1(C), patients with
medium biomarker levels are more likely benefited from the new therapy. Note that there are two
cutoff points in this case. They are c1α and c
2
α such that β(c
1
α) = β(c
2
α) = α. Hence patients with
biomarker levels in [c1α, c
2
α] should be sensitive patients.
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[Figure 1 about here.]
Secondly, researchers often want to know if a biomarker is good enough as a predictive marker
to distinguish sensitive patients from nonsensitive patients for the new treatment. This amounts to
a hypothesis testing that β(·) ≡ C. In this regard, if β(·) ≡ C, then the corresponding biomarker
can not predict the differential responses of individual patients to the new treatment. In this paper,
we test the null hypothesis of β(·) ≡ C based on the asymptotic distributions of the normalized
maximum deviations of the estimated BATE curves from the true BATE curves. We introduce two
methods for solving this problem. One is by constructing a test statistics, and the other one is by
constructing simultaneous confidence bands.
Thirdly, researchers are interested in comparing the clinical utility of different biomarkers based
on their capacities for predicting responses to a treatment. However, the definition (2) may not be
appropriate for such a comparison due to potentially different measurements of different biomarkers.
To compare different biomarkers, we may give a slightly modified definition of the BATE curve at
time t based on the quantile of the biomarker:
ψ(p, t) = log
{
λ(t|Z = 1, V = pip)
λ(t|Z = 0, V = pip)
}
, (4)
where pip is the pth quantile of the biomarker V , that is pip = inf{y : Fv(y) ≤ p}. Here, Fv(·) is
the cumulative distribution function of V . Similarly, in the special case that the BATE curve is
independent with time, we have ψ(p, t) ≡ ψ(p) for any t ∈ (0, τ).
Since ψ(p) is defined on the same scale between 0 and 1, we can compare the BATE curves of
two biomarkers to identify the more powerful one; that is we can distinguish “weak” and “strong”
predictive biomarkers. Take Figure 2 as an example. A weak predictive biomarker is the biomarker
whose BATE curve is near a constant (see the dashed line in Figure 2).
[Figure 2 about here.]
3. THE BATE CURVES OF A MULTIPLE-ARM RANDOMIZED CLINICAL TRIAL WITH
FULL COMPLIANCE
In Section 2 when there is one treatment arm, we proposed to use the BATE curve to select sensitive
patients for the treatment. When multiple treatments are involved in a randomized clinical trial,
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we further extend the use of the BATE curve to select the optimal treatment for an individual
patient. Next, we give detailed discussions on this extension .
3.1 Notation and Definitions
We first give some necessary notations. Let Z = (Z1, · · · , ZK)T be a vector of treatment group
indicators, where Zk = 1 for the kth treatment group and Zk = 0 otherwise, k = 1, · · · ,K, K > 1.
For i = 1, · · · , n, we let Ti(k) be the event time of an individual that would be observed if the
individual had received the kth treatment arm, where k = 1, · · · ,K, and Ti(0) be the event time
that would be observed if the individual had received the control arm. We also define the potential
conditional hazard rate functions as
λ(k)(t|v) = lim
∆t→0
P (t < Ti(k) ≤ t+∆t|Ti(k) > t, Vi = v)
∆t
, k = 1, · · · ,K,
λ(0)(t|v) = lim
∆t→0
P (t < Ti(0) ≤ t+∆t|Ti(0) > t, Vi = v)
∆t
.
Hence the BATE curve, at time t, of the kth treatment versus the control , based on the
multiplicative interaction, is defined as follows:
log
{
λ(k)(t|v)
λ(0)(t|v)
}
= βk(v, t). (5)
Similarly to the discuss in Section 2, in a randomized clinical trial with full compliance, we can
express the BATE curve, at time t, of the kth treatment as
log
{
λ(t|V = v,Z = ek)
λ(t|V = v,Z = 0K)
}
= βk(v, t), (6)
where λ(t|V = v,Z = ek) is the conditional hazard function of the observed survival time T , given
V = v and Z = ek.
We can also define the modified definition of the BATE curve at time t based on the quantile
of the biomarker as
log
{
λ(t|V = pip,Z = ek)
λ(t|V = pip,Z = 0K)
}
= ψk(p, t). (7)
Since we are focus on the special case that the BATE curve for each treatment arm is independent
with time, we have βk(v, t) ≡ βk(v) and ψk(v, t) ≡ ψk(v), for each k = 1, · · · ,K and for any
7
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t ∈ (0, τ). Consequently, we assume the following varying-coefficient proportional hazard regression
model for event time:
λ(t|Zi, Vi) = λ0(t) exp{βT (Vi)Zi + g(Vi)}, (8)
where β(·) = (β1(·), · · · , βK(·))T denotes the vector of the BATE curves. Apparently, the model
(3) is a special case of the model (8). This model has been studied by Fan, et al. (2006) and Cai,
et al. (2007). They proposed the estimates of coefficient functions by local partial likelihood and
established their pointwise asymptotic normalities. Their results, however, can only be used to
construct pointwise confidence intervals but cannot be used to construct simultaneous confidence
bands.
Since K > 1, we may also want to compare different treatments in order to find the optimal
treatment for individual patients. This amounts to the problem of comparing the estimated BATE
curves. We take Figure 3 (K = 3) as an example, which is also under the assumption that the
range of the biomarker is [0,1]. From Figure 3, we see that β3(v) < β2(v) < β1(v) < 0 when
v ∈ [0, a], that β2(v) < β3(v) < β1(v) < 0 when v ∈ (a, b], and that β1(v) < β2(v) < β3(v) < 0
when v ∈ (b, 1]. Hence, we would assign patients with the biomarker values in [0, a], (a, b] and (b, 1]
to receive Treatment 3, Treatment 2 and Treatment 1, respectively.
[Figure 3 about here.]
4. ESTIMATION AND ASYMPTOTIC PROPERTIES
Since the model (3) is a special case of the model (8), in this section we focus on estimation for the
model (8).
4.1 Estimation of BATE Curves and Cutoff Points
We are using a partial likelihood function with local polynomial (linear) fitting to estimate β(v)
and g(v).
For any given point v0, by Taylor series expansions, we obtain that
β(v) ≈ β(v0) + β′(v0)(v − v0) ≡ δ + γ(v − v0), and
g(v) ≈ g(v0) + g′(v0)(v − v0) ≡ a+ b(v − v0). (9)
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Let R(t) denote the set of the individuals at risk prior to time t and assume the observations
are independent. Using (9) for the data around v0 and utilizing a kernel function, we obtain the
following logarithm of the local partial-likelihood:
`n(δ, γ, b; v0) (10)
=
1
n
n∑
i=1
Kh(Vi − v0)∆i
{
δTZi + γTZi(Vi − v0) + b(Vi − v0)
− log(
∑
j∈R(Xi)
Kh(Vj − v0) exp{δTZj + γTZj(Vj − v0) + b(Vj − v0)})
}
,
where Kh(·) = K(·/h)/h is a symmetric kernel function, and h is a bandwidth. Suppose that (10)
is maximized at (δ̂, γ̂, b̂). Then β̂ = δ̂ is a local linear estimator of the coefficient function β(·)
at the point v0. An estimator of g′(·) at v0 is simply the local slope b̂(v0), i.e., ĝ′(v0) = ĝ. The
estimated curve ĝ(·) can be obtained by integrating ĝ′(v0), using the Trapezoidal rule (Hastie and
Tibshirani, 1990). For the purpose of ensuring the identifiability of g(·), we set g(0) = 0 without
loss of generality.
Next, we consider the estimation of the modified BATE curve ψ(p) = (ψ1(p), · · · , ψK(p))T . Note
that ψ(p) = β(pip). Hence, based on β̂(·), it remains to estimate the quantile pip of the continuous
biomarker V . The estimator pip is given by inf{y : F̂v(y) ≥ p}, where F̂v(·) denotes the empirical
estimator of Fv(·). As a result, the estimator of ψ(p) has the following form
ψ̂(p) = β̂(pip) = (β̂1(pip), · · · , β̂K(pip))T .
Since pip is a unique sample quantile, according to Koenker and Bassett (1978), if Fv(·) is continuous
and has a continuous and positive density, fv(·), at pip, then
√
n(pip− pip) converges to a mean zero
normal distribution, with the variance ω2 = p(1− p)/f2v (pip).
Given a clinical significant level α, since β(·) is a vector of smooth functions, and since Fv(·)
is continuous and has a continuous and positive density, we can directly select the tolerant cutoff
points cα,i such that βi(cα,i) = α, for the ith treatment arm.
Note that, for i = 1, · · · ,K, the tolerant cutoff points cα,i may not be unique due to the potential
non-monotonicity of βi(·). Hence we select the cutoff points as follows:
cα,i = {c : β̂i(c) = α}, and pα,i = {p : ψ̂i(p) = α},
i = 1, · · · ,K. Obviously, for i = 1, · · · ,K, we can also get pα,i by letting pα,i = F̂p(cα,i).
9
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4.2 Asymptotic Properties
To obtain asymptotic properties of the maximum partial likelihood estimator β̂1(v), we need a
few notations on the counting process. Let Ni(t) = I(Ti ≤ t,∆i = 1) and Yi(t) = I(Xi ≥ t).
Define Ft,i to be the failure, censoring and covariate information up to time t, and let Mi(t) =
Ni(t) − Yi(t)λ(t|Zi, Vi) be the Ft,i- martingale. Let µi =
∫
viK(v)dv, and νi =
∫
viK2(v)dv,
i = 1, 2, · · · . Let β0(·) and g0(·) be the true functions of β(·) and g(·), respectively. Denote
ρ(u, z, v0) = P (X ≥ u|z, v0) exp{βT0 (v0)z+ g0(v0)}.
For k = 0, 1, 2 and l = 0, 1, 2, we define
akl(u, v0) = f(v0)µlE{ρ(u,Z, v0)Z⊗k|V = v0},
where f(·) is the density of V and Z⊗k = 1,Z and ZZT for k = 0, 1 and 2, respectively.
Proposition 1: Under Conditions in the Appendix, we can obtain the following results:
(1). As n→∞,
sup
v∈V
|(β̂(v)− β0(v))| P−→ 0,
(2). For each v0 ∈ V,
√
nh(β̂(v0)− β0(v0)−
µ2
2
h2β′′(v0))
L−→ N(0, ν0Σ−1(v0)).
Here V is the compact support of the biomarker V , and β′′(v0) is the second derivative of β(v) at
v0 and
Σ(v0) =
∫ τ
0
{a20(u, v0)
− a10(u, v0)aT10(u, v0)a−100 (u, v0)λ0(u)}du.
Proof of Proposition 1 can be found in Fan, et al. (2006), and is omitted here for saving some
space.
Let ψ0(·) denote the true function of ψ(·). Next, we state the pointwise asymptotic distribution
of ψ̂(p),
10
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Theorem 1 Under Conditions in the Appendix, if fv(·) is continuous and positive at pip, we can
obtain the following asymptotic normality result:
√
nh(ψ̂(p)− ψ0(p)− µ22 h
2β′′(pip))
L−→ N(0, ν0Σ−1(pip)).
The proof of Theorem 1 can be directly obtained by Proposition 1 and the fact that pip is
√
n-
consistent.
5. HYPOTHESIS TESTING BASED ON ASYMPTOTIC DISTRIBUTIONS OF THE
NORMALIZED MAXIMUM DEVIATIONS
As discussed in Section 2, the usefulness of a predictive biomarker can be tested, based on a null
hypothesis that the BATE curve is a constant. In this section we propose two methods to test this
null hypothesis. The basic idea is using the asymptotic distribution of the normalized maximum
deviations of the estimated BATE curves from the true BATE curves.
5.1 Asymptotic Distributions of the Normalized Maximum Deviations
For any function b(v) and any matrix B(v) = (bij(v))K , we define ‖b‖∞ = supv∈[0,1] |b(v)| and
‖B‖∞ =
(
K∑
i=1
K∑
j=1
‖bij‖∞
)1/2
. We now give our main results below.
Theorem 2 Assume that Conditions in the Appendix hold, if [0, 1] ⊆ V, and h = n−d, 1/5 ≤ d <
1− 2/s, s > 2, then we have for k = 1, · · · ,K,
P{{2 log(1/h)}1/2
(
‖ β̂k−βk−bias(β̂k)σk ‖∞ − dn
)
< x}
→ exp{−2 exp(−x)}, (11)
where σ2k(v) is the kth diagonal element of ν0Σ(v), bias(β̂k(v)) = e
T
k,K
µ2
2 h
2β′′(v), ek,K is a K−dimensional
vector with the kth element 1 and else 0. Here
dn = {2 log(1/h)}1/2 + 1{2 log(1/h)}1/2 log
{∫
(K ′(v))2dv
4ν0pi
}
.
If the supremum in Theorem 2 is taken on an interval [a, b] instead of [0, 1], then by replacing
log(1/h) in (11) and dn with log((b − a)/h), Theorem 2 continues to hold. The proof of Theorem
2 is given in Appendix C.
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5.2 Hypothesis Testing of the BATE Curves
Researchers often want to know if a biomarker is good enough as a predictive marker to distinguish
sensitive patients from nonsensitive patients for one treatment of interest, or if one particular
treatment is noneffective for all patients. This amounts to testing whether its BATE curve is
equivalent to a non-zero constant or zero. Without loss of generality, suppose that we are interested
in the kth (1 ≤ k ≤ K) treatment, and we consider the hypothesis problem over [0, 1]. Hence we
state the null and alternative hypothesis as follows:
H0 : βk(v) = C v.s H1 : βh(v) 6= C (12)
or
H∗0 : ψk(p) = C v.s H
∗
1 : ψk(p) 6= C. (13)
Under the null hypothesis H0, the model (8) is a semiparametric varying coefficient Cox’s hazard
ratio model. We are estimating C using a profile method.
Note that σk(v) and bias(β̂k) in (11) are unknown, we can not directly use Theorem 2 to
construct test statistics. Hence it’s required to first estimate the bias and variance of β̂k(u),
k = 1, · · · ,K. From the expressions for the asymptotic bias, bias(β̂(v)), and variance, Σ(v), of
β̂(v) in Appendix A-C, we can obtain their consistent estimators b̂ias(β̂(v)) and Σ̂(v) , which are
also given in Appendix A-C before the proof of Theorem 3.
Theorem 3 Under the conditions of Theorem 2, if the third derivative of β(·) is continuous on
[0, 1], then we have for k = 1, · · · ,K,
P{{2 log(1/h)}1/2
(
‖ β̂k−βk−b̂ias(β̂k)σ̂k ‖∞ − dn
)
< x}
→ exp{−2 exp(−x)} , (14)
where σ̂2k(v) is the kth diagonal element of ν0Σ̂(v) and b̂ias(β̂k(v)) is the kth element of b̂ias(β̂(v)).
Next, we establish the the asymptotic distribution of the maximum deviation of ψ̂(p).
Theorem 4 Under the conditions of Theorem 2, if the third derivative of β(·) is continuous on
[0, 1] and fv(·) is continuous and positive, then we have for k = 1, · · · ,K,
P{{2 log(1/h)}1/2
(
‖ ψ̂k(p)−ψk(p)−b̂ias(ψ̂k(p))σ̂k ‖∞ − dn
)
< x}
→ exp{−2 exp(−x)} , (15)
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where b̂ias(ψ̂k(p)) is same as b̂ias(β̂(pip)).
The proofs of Theorem 3 and Theorem 4 are given in Appendix C.
According to Theorem 3 and Theorem 4, we can test the null hypothesis, defined by (12) (or
(13)), by calculating the following test statistics
{2 log(1/h)}1/2(‖ β̂k − Ĉ − b̂ias(β̂k)
σ̂1
‖∞ − dn),
or
{2 log(1/h)}1/2(‖ ψ̂k − Ĉ − b̂ias(ψ̂k)
σ̂1
‖∞ − dn)
and rejectingH0 (orH∗0 ) when test statistic exceeds the asymptotic critical value vα∗ = − log(−0.5 log(1−
α∗)) for the nominal level α∗.
An alternative method for the hypothesis testing problem (12) (or (13)) is to see whether Ĉ
falls inside the simultaneous confidence band of βk(v) (or ψk(p)), which can also be constructed
based on the asymptotic distribution of the maximum deviations. It is followed from Theorem 3
and Theorem 4 that for k = 1, · · · ,K, the (1− α∗)% confidence bands of β̂k(v) and ψ̂k(p) on [0, 1]
is
(β̂k(v)− b̂ias(β̂k(v))± qn,k(v)), (16)
and
(ψ̂k(p)− b̂ias(ψ̂k(p))± qn,k(pip)), (17)
respectively, where qn,k(v) = (dn + [log 2− log{− log(1− α∗)}](2 log(1/h))−1/2)σ̂k(v).
Remark 1 Note that, by using the MSE optimal bandwidth hopt, whose converge rate is Op(n−1/5),
we obtain a asymptotically biased estimator, β̂k(v), of βk(v). Although we can propose a consistent
estimate of the asymptotic bias of β̂k(v), it is unstable. According to Theorem 2, we can choose a
bandwidth which converges to 0 at a slightly faster rate than the optimal bandwidth rate Op(n−1/5)
to obtain an asymptotically unbiased estimate. In the simulation studies, we ignore the asymptotic
biases based on the two-stage method of Fan and Zhang (2000): We first select the optimal bandwidth
hopt for estimating the coefficient functions, and then use hopt/2 for calculating test statistics or
constructing confidence bands.
13
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Remark 2 It’s well known that based on the asymptotically unbiased estimator by choosing a band-
width which converges to 0 at a slightly faster rate than the optimal bandwidth rate, the test statistics’
approximations are not very accurate (Hall 1993). Tian, Zucker and Wei (2005) argued that by
employe an alternative strategy based on the Lin, Fleming and Wei (1994) stochastic perturbation
technique, we can obtain a more accurate approximation to the distribution of the maximum devi-
ations of β̂k(·) from βk(·). However, our simulations studied in the next section show that by using
the two-stage method, we can also obtain accurate approximations.
6. SIMULATION STUDIES
In this section, we carried out two simulation studies to examine the finite-sample properties of the
proposed methods. The first simulation study assessed the performance of the proposed estimators
for the BATE curves, and the second simulation study evaluated the type I error rate of the
proposed test for the null hypothesis that some BATE curves are a constant. In both simulation
studies, the sample size was set to be 500, and the number of the simulation was chosen to be 500.
In the first simulation study, we generated the failure time data from the following varying-
coefficient hazard regression model: λ(t|V,Z1, Z2) = λ0(t) exp{β1(V )Z1 + β2(V )Z2 + g(V )}, where
β1(v) = 3v(1.5 − v), β2(v) = 2 sin(3v), g(v) = v2 and λ0(t) = 3t2/5. We then generated V from
a normal distribution with mean 1 and variance 1/9. Covariates Z1 and Z2 were generated form
multiple Bernoulli random variables (z1, z2, z1 + z2), and each component took value 0 or 1 with
probability of being 1 as 0.3, 0.35 and 0.65, respectively. We generated the censoring time C from
an exponential distribution with mean cc, where cc was chosen to yield a approximately censoring
rate (CR) of 20% and 40%, respectively. For each censoring rate, we also calculated the standard
deviations (SDs), the average standard errors (SEs), and the 95% confidence interval coverage rates
(CPs) of β̂1(v), β̂2(v) and ψ̂1(p), ψ̂2(p). Simulation results are represented in Table 1 and Figure
4-5. The results show that the proposed estimators perform well.
[Figure 4 about here.]
[Figure 5 about here.]
[Table 1 about here.]
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In the second simulation study, we focus on the performance of the proposed hypothesis test
for the first null hypothesis that the functional coefficient β1(·) is a constant. That is we consider
the null hypotheses: H0 : β1(·) ≡ C, which implies that the causal effect of the first treatment
versus control does not depend on the value of the biomarker. We generated failure times from
the hazard regression model λ(t|V, Z1, Z2) = 0.6t2 exp{β1(V )Z1 + β2(V )Z2 + V 2}. To evaluate
the proposed method, we carried out several different simulation studies. We let β1(v) = −1 and
β2(v) = 2 sin(3v),− exp(v), 0, respectively. For each case, we calculated the type I error rates
based on 500 simulations and 500 sample size, for the significant level α∗ = 0.05, 0.01, respectively.
Results are reported in Table 2. For each case, we chose cc to yield an approximately censoring rate
of 20%, and generated covariates Z1, Z2 and V in the same way as in the first simulation study.
[Table 2 about here.]
In the both simulation studies, we adapted the method of Fan and Huang (2005) to select
the optimal bandwidth ĥopt, which was found to be round 0.113 in our setting, for estimating
the coefficient functions, and then as discussed in Remark 1, we used ĥopt/2 for calculating test
statistics or constructing confidence bands (Fan and Zhang 2000).
From Table 2, we see that by using the two-stage method for calculating test statistics or
constructing confidence bands, type I error rates are very close to their corresponding significant
levels α∗.
7. EXAMPLE
We illustrate the application of the proposed method in a real-world clinical study on the role
of c-myc in selecting the optimal treatment for patients with colon cancer (Augenlicht (1997)).
In this clinical trial, patients with colon cancer can be treated by surgery alone or surgery plus
chemotherapy. Surgery alone is less invasive and less expensive than surgery plus chemotherapy. It
is desirable to identify the patients who may benefit more from surgery plus chemotherapy based
on their biomarkers. Based on a study conducted by the Eastern Cooperative Oncology Group
(ECOG), Augenlicht (1997) suggested that the c-myc oncogene may be a predictive biomarker for
patients with colon cancer. Using a subset of the cases from this clinical trial, Li and Ryan (2006)
15
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found that there might be an interaction between the c-myc oncogene expression level and the two
treatments on overall survival and disease progression free survival.
In this section, we apply our method to this data set to assess the role of c-myc oncogene in
predicting response to treatment and distinguish sensitive patients from nonsensitive patients based
on their c-myc levels. Disease progression free survivals of a total of 124 patients randomized to
receive surgery alone or surgery plus chemotherapy or other treatments were measured. We let Vi
be the c-myc oncogene expression level of the ith patient, Zi1 and Zi2 be the indicators of receiving
other treatments and receiving surgery plus chemotherapy, respectively. We consider the following
model:
λ(t|Zi, Vi) = λ0(t) exp{β1(Vi)Zi1 + β2(Vi)Zi2 + g(Vi)}. (18)
We fit the model (18) for the progression free survival. The 95% confidence limits and 95%
confidence band are calculated by a sandwich method. The Gaussian kernel is employed, and the
bandwidth is chosen to be 25% of the interval length. Results are presented in Figure 6 and Figure
7.
[Figure 6 about here.]
[Figure 7 about here.]
First we consider the hypothesis problems of whether the BATE curves or modified BATE curves
are constants. We perform the following four hypothesis tests. H01 : β1(v) ≡ 0; H02 : β1(v) ≡ C1;
H03 : β1(v) ≡ 0; and H04 : β1(v) ≡ C2, where C1 and C2 are unspecified constants. We obtain the
p−value of each null hypothesis as follows: p1 = 0.056, p2 = 0.002, p3 = 0.052 and p4 = 0.005,
respectively. The results show (1) that the effect of the treatment arm of surgery only versus the
other treatment arm does not depend on the biomarker c−myc value and (2) that the treatment
effect of the treatment arm of surgery plus chemotherapy versus the surgery varies with patients’
c−myc levels.
As we discussed in Section 5, we can also test the null hypothesis problems by constructing
confidence bands of the estimators of β1(v) and β2(v), and the resulting confidence bands are
displayed in Figure 6 and Figure 7. From Figure 6, we can see that the constant curve 0 falls between
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the upper and lower confidence bands of the BATE or modified BATE curve of the treatment arm
of other treatments. This result is same as the conclusion (1) as above, which also implies that the
treatment effect of the other treatment versus the surgery only does not depend patient’s c−myc
levels. From Figure 7, we can see that, for the treatment arm of surgery plus chemotherapy, we
reject the null hypothesis that the treatment effect of the surgery plus chemotherapy versus surgery
only is the same, regarding less patient’s c−myc values. This conclusion implies that the biomarker
c−myc is capable of predicting the treatment effect of surgery plus chemotherapy, selecting cutoff
points and distinguishing sensitive patients from nonsensitive patients.
Next, for the treatment arm of surgery plus chemotherapy, we consider three different clinical
significant levels: α1 = − log(8) ≈ −2.08, α2 = − log(4) ≈ −1.39 and α3 = − log(2) ≈ −0.69, which
imply that the risks of having cancer recurrence for patients in control group (surgery only) are
eight times, four times and twice, respectively, as large as the risk in the treatment group of surgery
plus chemotherapy. The cutoff points for the chosen clinical significant levels are shown in Figure 7.
From Figure 7(A), we see that a patient with c−myc level no less than the cutoff point cα1 ≈ 3.254
should be treated by surgery plus chemotherapy, if this patient is willing to take at most one eighth
risk of having cancer recurrence, as large as being treated by surgery only. Similarly, a patient
with c − myc level no less than the cutoff point cα2 ≈ 2.689 (cα3 ≈ 1.716) should be treated by
surgery plus chemotherapy, if one-fourth (a half) risk of having cancer recurrence can be acceptable.
Based on the quantile of c −myc, we also get the cutoff points for each clinical significant levels,
see Figure 7(B). From Figure 7(B), we can see that the cutoff points are pα1 = F̂p(cα1) ≈ 0.955,
pα2 = F̂p(cα2) ≈ 0.923 and pα3 = F̂p(cα3) ≈ 0.737, respectively. Then we can conclude that, if
taking the treatment of surgery plus chemotherapy, only around 4.5% patients will reduce the risk
of having cancer recurrence to one eighth of the risk if taking surgery only, around 7.7% patients
will reduce the risk of having cancer recurrence to one fourth of the risk if taking surgery only, and
around 26.3% patients will reduce the risk of having cancer recurrence to a half of the risk if taking
surgery only. These results are very helpful for making medical policies.
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Hosted by The Berkeley Electronic Press
8. DISCUSSION
In this paper, we have introduced a new concept, the BATE curve, to represent the predictive
ability of a biomarker in selecting patients who respond better to one particular treatment over
another treatment, called sensible patients, when patient’s outcome is time-to-event. Compared
to the existing methods, the BATE curve not only visually displays the treatment effect on the
patient’s outcome as a function of the biomarker value but also allows one to compare the relative
performance of different predictive biomarkers that may have different scales. We have also pro-
posed semi-parametric time-varying coefficient regression methods for estimating the BATE curves
and their confidence bands.
The proposed estimation methods have the following technical advantages over the existing
methods. (1) By assuming the interaction between a continuous-scale biomarker and the treatment
group is a continuous function of the biomarker, the proposed varying coefficient models are flexible
enough to indicate both local and global association between treatment and the biomarker value.
(2) We propose a new semi-parametric test for the null hypothesis that the entire BATE curve of
a biomarker is constant; that is, the biomarker does not have predictive power in selecting sensible
patients to one particular treatment.
Although this paper has focused on multiplicative interaction to represent the treatment effect
when the patient’s outcome is time-to-event, the proposed methods can be easily extended to
the additive interaction between the treatment groups and biomarkers. In fact, we have already
developed the BATE curve and associated inference procedures for the additive interactions. Since
in the survival analysis, the multiplicative interaction effects, which describes derivations from
multiplicative joint effects, are commonly used, due to the limited space in this paper, we have only
reported the results for multiplicative interaction effects. The results on the BATE curves, based
on additive interactions, will be reported in a technical report.
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APPENDIX A: ASSUMPTIONS
We list the following assumptions in the Appendix for our results.
1. For s > 2, E|Zj |2s <∞, j = 1, · · · ,K.
2. The biomarker V has a compact support V, in which fv(v) is continuous, and infv∈Vε fv(v) > 0
for some ε > 0, where Vε = {v : inf
v0∈V
|v − v0| ≤ ε}.
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3. Let Ω(v) = diag (Σ(v),Γ(v)), where
Γ(v) =
 ∫ τ0 a22(u, v)dΛ0(u) ∫ τ0 a12(u, v)dΛ0(u)∫ τ
0 a
T
12(u, v)dΛ0(u)
∫ τ
0 a22(u, v)dΛ0(u)
 .
Then Ω(v) is non-singular for any v ∈ Vε, Σ(v) is positive definite for any v ∈ Vε, and the
elements in Ω(v) are continuous on the compact support V.
4. E(Z2sj |V = v) is bounded for v ∈ V, j = 1, · · · ,K.
∫
λ0(t)dt < ∞, and ‖fv(v)‖V < ∞, where
‖ · ‖V is the sup-norm of a function on V.
5. Functions β(·) and g(·) have continuous second derivatives on the compact support V.
6. The kernel function K(·) is a bounded, symmetric density function and uniformly continuous.
Furthermore, K(x)→ 0 as x→∞, ∫ |K(x)|dx <∞ and ∫ K2(x)dx <∞.
7. The conditional probability P (X ≥ u|z, v) is equi-continuous in the arguments (u, v) on [0, τ ]×
Vε.
8. Let
s∗k(u, ζ, v0) = f(v0)
∫
E
[
P (X ≥ u|z, v0)Φ(ζ, y)R(y)⊗k|v = v0
]
K(y)dy,
where k = 0, 1, 2, R(y) = (ZT ,ZT y, y)T , and
Φ(ζ, y) = exp{ζTR(y) + βT (v)Z}.
We suppose that for k = 0, 1, 2, s∗k(u, ζ, v) is bounded away form 0 on the product space
[0, τ ]×C1 × Vε, where C1 ∈ R2K+1; that is
inf
u∈[0,τ ]
inf
ζ∈C1
inf
v∈Vε
s∗k(u, ζ, v) > 0,
and
sup
(βT ,g)∈C2
E|Z|2 exp{βTZ+ g} <∞,
where C2 ∈ RK+1
9. We have nh/ logn→∞ as n→∞, and nh5 is bounded.
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APPENDIX B: TECHNICAL LEMMAS
Before we prove the theorems, we present several lemmas first as follows. Lemma 1-lemma 3 are
needed for the proofs of lemma 4, Theorem 2, Theorem 3, and Theorem 4. Lemma 4 is needed for
the proof of Theorem 2.
Given t ∈ [0, τ ], let (ξ1(t), V1), · · · , (ξn(t), Vn) be an i.i.d. random sample from (ξ(t), V ). We
assume that V and the kernel function K(·) satisfy the conditions in A.1. We further assume that
ξ satisfies the following three conditions: (1) for an s > 2, sup
t∈[0,τ ]
E|ξ(t)|s < ∞; (2) the function
σ2(v) is bounded away from zero for v ∈ [0, 1] and has a bounded first derivative on [0,1], where
σ2(v) = E{∫ τ0 ξ2(t)λ(t)dt|V = v}; and (3) supx supt∈[0,τ ] ∫ |y(t)|sf(y(t), x)dy = cx < ∞, where
f(y(t), x) is the joint density of (ξ(t), V ). Let
m(v) =
1
n
σ−1(v)f−1/2(v)
n∑
i=1
∫ τ
0
ξi(t)Kh(Vi − v)dMi(t).
For the process m(v), we have the following lemma 1
Lemma 1 Suppose Assumptions 6-7 hold. If h = n−b, for some 0 < b < 1− 2/s, we have
P{(−2 log h)1/2
(√
nh]ν−1/20 ‖m(v)‖∞ − dn
)
< x}
→ exp{−2 exp{−x}}. (19)
Proof. Note that
m(v) =
1
n
σ−1(v)f−1/2(v)
n∑
i=1
∫ τ
0
ξi(t)Kh(Vi − v)dMi(t)
=
1
n
σ−1(v)f−1/2(v)
n∑
i=1
Kh(Vi − v)
∫ τ
0
ξi(t)dMi(t),
with M∗i (s, v) =
∫ s
0 ξi(t)dMi(t) being a Fs martingale for s ∈ (0, τ ] and i = 1, · · · , n. Then
M∗i (τ, v), i = 1, · · · , n, is an i.i.d. random variable sequence, E|M∗i (τ, v)|s <∞, E{M∗i (τ, v)} = 0,
and V ar{M∗i (τ, v)} = σ2(v) for any v ∈ [0, 1]. Hence, according to Lemma 1 of Fan and Zhang
(2000), (19) follows.
Similarly, we define
m∗(v) =
1
n
σ∗−1(v)f−1/2(v)
n∑
i=1
∫ τ
0
ξi(t)Kh(Vi − v)dΛi(t),
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where σ∗2(v) = V ar{∫ τ0 ξ(t)λ(t)dt|V = v}, and σ∗2(v) is bounded away from zero for v ∈ [0, 1] and
has a bounded first derivative on [0,1]. Hence for the process m∗(v), we have a similar lemma to
lemma 1, as stated as lemma 2 below.
Lemma 2 Suppose Assumptions 6-7 hold. If h = n−b, for some 0 < b < 1− 2/s, we have
P{(−2 log h)1/2
(√
nh]ν−1/20 ‖m∗(v)− E{m∗(v)}‖∞ − dn
)
< x}
→ exp{−2 exp{−x}}. (20)
The proof of lemma 2 can be obtained directly by the Lemma 1 of Fan and Zhang (2000).
Lemma 3 Let θ(v0) = (δT , hγT , hb)T , Z∗i = (Z
T
i ,Z
T
i (Vi− v0)/h, (Vi− v0)/h)T , where i = 1, · · · , n.
Let θ0(v0) = (βT0 (v0), hβ
′T
0 (v0), hg
′(v0))T be the true value of θ(v0), for any v0 ∈ V. Define
Snkl(t, θ0(v0)) =
1
n
n∑
i=1
Yi(t) exp{θT0 (v0)Z∗i + g0(v0)}Kh(Vi − v0)(Z⊗ki )(
Vi − v0
h
)l,
S∗nkl(t, v0) =
1
n
n∑
i=1
Yi(t) exp{βT0 (v0)Zi + g0(v0)}Kh(Vi − v0)(Z⊗ki )(
Vi − v0
h
)l,
for k = 0, 1, 2, l = 0, 1, 2. Then if Assumptions 1-7 hold, we have
sup
t∈[0,τ ]
‖S∗nkl(t, v0)− akl(t, v0)‖∞ = Op
({
log(1/h)
nh
}1/2)
,
and
sup
t∈[0,τ ]
‖Snkl(t, θ0(v0))− akl(t, v0)‖∞ = Op
({
log(1/h)
nh
}1/2
+ h2
)
,
where k = 0, 1, 2, l = 0, 1, 2.
Proof. Note that for any t ∈ [0, τ ], k = 0, 1, 2, l = 0, 1, 2 and v0 ∈ V , akl(t, v0) = E{S∗nkl(t, v0)},
and Cov{√nS∗nkl(t, v0)} = Op(h). Hence according to Theorem 1 of Silverman (1978), we obtain
the following result:
{1
h
log(
1
h
)}−1/2√n sup
t∈[0,τ ]
sup
v∈V
|S∗nkl(t, v0)− akl(t, v0)| = Op(1),
which yields that
sup
t∈[0,τ ]
‖S∗nkl(t, v0)− akl(t, v0)‖∞ = Op
({
log(1/h)
nh
}1/2)
,
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k = 0, 1, 2, l = 0, 1, 2. Furthermore, since
sup
t∈[0,τ ]
‖Snkl(t, θ0(v0))− akl(t, v0)‖∞
≤ sup
t∈[0,τ ]
‖Snkl(t, v0)− S∗nkl(t, v0)‖∞ + sup
t∈[0,τ ]
‖S∗nkl(t, v0)− akl(t, v0)‖∞,
we just need to prove that the first term on the right-hand side has the order of Op(h2) to complete
the proof. Notice that for k = 0, 1, 2, l = 0, 1, 2,
sup
t∈[0,τ ]
‖Snkl(t, θ0(v0))− S∗nkl(t, v0)‖∞
= sup
t∈[0,τ ]
‖ 1
n
n∑
i=1
Yi(t)Kh(Vi − v0)(Z⊗k)(Vi − v0
h
)l
[exp{θT0 (v0)Z∗i + g0(v0)} − exp{βT0 (v0)Zi + g0(v0)}]‖∞
= sup
t∈[0,τ ]
‖ 1
n
n∑
i=1
Yi(t)Kh(Vi − v0)(Z⊗k)(Vi − v0
h
)l
exp{ηi(v0)}12[β
′′T
0 (V
∗
i )Zi + g
′′
0(V
∗
i )](Vi − v0)2‖∞,
where ηi(v0) is between βT0 (v0)Zi + g0(v0) and θ
T
0 (v0)Z
∗
i + g0(v0), and V
∗
i is between v0 and Vi,
i = 1, · · · , n. Hence it follows from Theorem 1 of Silverman (1978) that
sup
t∈[0,τ ]
‖ 1
n
n∑
i=1
Yi(t)Kh(Vi − v0)(Z⊗k)(Vi − v0
h
)l
exp{ηi(v0)}12[β
′′T
0 (V
∗
i )Zi + g
′′
0(V
∗
i )](Vi − v0)2‖∞
= sup
t∈[0,τ ]
‖h
2
n
n∑
i=1
Yi(t)Kh(Vi − v0)(Z⊗k)(Vi − v0
h
)l+2
exp{ηi(v0)}12[β
′′T
0 (V
∗
i )Zi + g
′′
0(V
∗
i )]‖∞
= Op(h2).
Thus lemma 3 follows.
Lemma 4 If Assumptions 1-7 hold, then
‖ − ∂
2`n(θ∗(v0); v0)
∂θ∂θT
|θ=θ∗(v0) − Ω(v0)‖∞
= Op
({
log(1/h)
nh
}1/2
+ h2 + ‖θ̂(v0)− θ0(v0)‖∞
)
, (21)
where θ∗(v0) is between θ̂(v0) and θ0(v0), for any v0 ∈ V.
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Proof. Let
Φ(t, θ∗(v0)) =
{
Sn20(t, θ∗(v0)) Sn21(t, θ∗(v0)) Sn11(t, θ∗(v0))
Sn21(t, θ∗(v0)) Sn22(t, θ∗(v0)) Sn12(t, θ∗(v0))
Sn11(t, θ∗(v0)) Sn12(t, θ∗(v0)) Sn02(t, θ∗(v0))
Sn00(t, θ∗(v0))
−

Sn10(t, θ∗(v0))
Sn11(t, θ∗(v0))
Sn01(t, θ∗(v0))

⊗2}
S−2n00(t, θ
∗(v0)), and
ϕ(t, v∗) =
{
a20(t, v∗) a21(t, v∗) a11(t, v∗)
a21(t, v∗) a22(t, v∗) a12(t, v∗)
a11(t, v∗) a12(t, v∗) a02(t, v∗)
 a00(t, v∗)
−

a10(t, v∗))
a11(t, v∗)
a01(t, v∗)

⊗2}
a−200 (t, v
∗),
where v∗ ∈ V such that θ0(v∗) = θ∗(v0). Hence,
‖ − ∂
2`n(θ∗(v0); v0)
∂θ∂θT
|θ=θ∗(v0) − Ω(v0)‖∞
≤ ‖ 1
n
n∑
i=1
∫ τ
0
{Φ(t, θ∗(v0))− ϕ(t, v∗)}dNi(t)‖∞ + ‖ 1
n
n∑
i=1
∫ τ
0
ϕ(t, v0)dMi(t)‖∞
+‖ 1
n
n∑
i=1
∫ τ
0
{ϕ(t, v0)− ϕ(t, v∗)}dNi(t)‖∞
+‖ 1
n
n∑
i=1
∫ τ
0
ϕ(t, v0)Yi(t) exp{βT0 (Vi)Zi + g0(Vi)}dΛ0(t)− Ω(v0)‖∞
≡ In1 + In2 + In3 + In4. (22)
According to Lemma 3, we have In1 = Op
({
log(1/h)
nh
}1/2
+ h2
)
. Notice that it follows from lemma
1 and lemma 2 that
‖ 1
n
n∑
i=1
Kh(Vi − v)
∫ τ
0
ξi(t)dMi(t)‖∞ = Op
({
log(1/h)
nh
}1/2)
, (23)
‖ 1
n
n∑
i=1
Kh(Vi − v)
∫ τ
0
ξi(t)dNi(t)− E{m∗(v)}‖∞ = Op
({
log(1/h)
nh
}1/2)
, (24)
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for any compact support V of V . Since
In2 = ‖ 1
n
n∑
i=1
∫ τ
0
∂ϕ(t, v)
∂θ
|θ=θ0(v0){θ0(v∗)− θ0(v0)}(1 + op(|θ0(v∗)− θ0(v0)|))dNi(t)‖∞,
it follows from (24) that In2 = Op(‖θ0(v∗) − θ0(v0)‖∞) = Op(‖θ̂(v0) − θ0(v0)‖∞). Similarly, since
K(·) is symmetric, (23) yields that In3 = Op
({
log(1/h)
nh
}1/2)
and Lemma 3 yields that In4 =
Op
({
log(1/h)
nh
}1/2)
. Thus Lemma 4 holds.
APPENDIX C: PROOF OF THE MAIN RESULTS
Proof of Theorem 2. For any v0 ∈ V,
−∂`n(θ0(v0); v0)
∂θ
|θ=θ0(v0) =
∂2`n(θ∗(v0); v0)
∂θ∂θT
|θ=θ∗(v0)(θ̂(v0)− θ0(v0)),
where θ∗(v0) is between θ̂(v0) and θ0(v0). Hence we have
‖θ̂(v0)− θ0(v0)‖∞ = ‖
[
−∂
2`n(θ∗(v0); v0)
∂θ∂θT
|θ=θ∗(v0)
]−1
∂`n(θ∗(v0); v0)
∂θ
|θ=θ0(v0)‖∞. (25)
Next, we focus on ‖∂`n(θ∗(v0);v0)∂θ |θ=θ0(v0)‖∞. Let ζn(t, θ0(v0)) = (STn10(t, θ0(v0)), STn11(t, θ0(v0)),
Sn01(t, θ0(v0)))T . Then
∂`n(θ∗(v0); v0)
∂θ
|θ=θ0(v0)
=
1
n
n∑
i=1
∫ τ
0
Kh(Vi − v0){Z∗i −
ζn(t, θ0(v0))
Sn00(t, θ0(v0))
}dNi(t)
=
1
n
n∑
i=1
∫ τ
0
Kh(Vi − v0){Z∗i −
ζn(t, θ0(v0))
Sn00(t, θ0(v0))
}dMi(t)
+
1
n
n∑
i=1
∫ τ
0
Kh(Vi − v0){Z∗i −
ζn(t, θ0(v0))
Sn00(t, θ0(v0))
}Yi(t) exp{βT0 (Vi)Zi + g0(Vi)}dΛ0(t)
≡ I∗n1 + I∗n2
By Lemma 1 and Lemma 3, we have
‖I∗n1 −
1
n
n∑
i=1
∫ τ
0
Kh(Vi − v0){Z∗i −
(aT10(t, v0), a
T
11(t, v0), a01(t, v0))
T
a00(t, v0)
}dMi(t)‖∞
≤ Op
({
log(1/h)
nh
}1/2
h2 +
{
log(1/h)
nh
})
, (26)
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and
‖I∗n2 −
1
2
µ2h
2Ω(v0)(β
′′T
0 (v0), 0
T
K , g
′′
0(v0))
T ‖∞ ≤ Op(h3). (27)
Note that (A+ hB)−1 = A−1 − hA−1BA−1 +O(h2), thus it follows from Lemma 4 that
‖
[
−∂
2`n(θ∗(v0); v0)
∂θ∂θT
|θ=θ∗(v0)
]−1
− Ω−1(v0)|∞
= Op
({
log(1/h)
nh
}1/2
+ h2 + ‖θ̂(v0)− θ0(v0)‖∞
)
. (28)
As a result, by combining (25)-(28), we have
‖
√
nh{θ̂(v0)− θ0(v0)− 12µ2h
2(β
′′T
0 (v0), 0
T
K , g
′′
0(v0))
T }
−
√
h
n
n∑
i=1
∫ τ
0
Kh(Vi − v0){Z∗i −
(aT10(t, v0), a
T
11(t, v0), a01(t, v0))
T
a00(t, v0)
}dMi(t)‖∞
≤ Op
(
{log(1/h)}1/2 h2 +
{
log(1/h)√
nh
})
+Op
(√
nh7
)
+Op
(
‖θ̂(v0)− θ0(v0)‖∞ {log(1/h)}1/2
)
.
It follows from (23) and ‖θ̂(v0)−θ0(v0)‖∞ = op(1) that ‖θ̂(v0)−θ0(v0)‖∞ = Op
({
log(1/h)
nh
}1/2
+h2
)
,
which yields that
‖
√
nh{θ̂(v0)− θ0(v0)− 12µ2h
2(β
′′T
0 (v0), 0
T
K , g
′′
0(v0))
T }
−
√
h
n
n∑
i=1
∫ τ
0
Kh(Vi − v0){Z∗i −
(aT10(t, v0), a
T
11(t, v0), a01(t, v0))
T
a00(t, v0)
}dMi(t)‖∞
≤ Op
(
log(1/h)
nh
+ h2 {log(1/h)}1/2 +
√
nh7
)
.
Hence, Theorem 2 follows.
Next, we derive the consistent estimators of the asymptotic bias and covariance of β̂(·). Ac-
cording to Fan et al. (2006), we can estimate the asymptotic bias and covariance by
b̂ias(β̂(v)) = A−1n (v)Bn(v), Σ̂
−1(v) = (nh)−1A−1n (v)Π̂n(v)A
−1
n (v),
and
Π̂n(v) =
ν−10
nh
n∑
i=1
∫ τ
0
K2h(Vi − v)
{
Zi − Sn10(t, θ̂(v))
Sn00(t, θ̂(v))
}⊗2
dNi(t),
27
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respectively, where
An(v) =
1
n
n∑
i=1
∫ τ
0
Kh(Vi − v)
Sn20(t, θ̂(v))
Sn00(t, θ̂(v))
−
{
Sn10(t, θ̂(v))
Sn00(t, θ̂(v))
}⊗2 dNi(t),
Bn(v) =
1
n
n∑
i=1
∫ τ
0
Kh(Vi − v)
{
Zi − Sn10(t, θ̂(v))
Sn00(t, θ̂(v))
}
dNi(t).
Proof of Theorem 3. Note that ‖θ̂(v)− θ0(v)‖∞ = Op
({
log(1/h)
nh
}1/2
+ h2
)
; hence it follows
from lemma 3 that
‖An(v)− Σ(v)‖∞
≤ ‖An(v)− 1
n
n∑
i=1
∫ τ
0
Kh(Vi − v)
[
Sn20(t, θ0(v))
Sn00(t, θ0(v))
−
{
Sn10(t, θ0(v))
Sn00(t, θ0(v))
}⊗2]
dNi(t)‖∞
+‖ 1
n
n∑
i=1
∫ τ
0
Kh(Vi − v)
[
Sn20(t, θ0(v))
Sn00(t, θ0(v))
−
{
Sn10(t, θ0(v))
Sn00(t, θ0(v))
}⊗2]
dNi(t)− Σ(v)‖∞
= Op
({
log(1/h)
nh
}1/2
+ h2
)
.
On the other hand,
‖Bn(v)− 12µ2h
2Σ(v)β′′(v)‖∞
≤ ‖ 1
n
n∑
i=1
∫ τ
0
Kh(Vi − v)
{
Zi − Sn10(t, θ̂(v))
Sn00(t, θ̂(v))
}
dMi(t)‖∞
+‖ 1
n
n∑
i=1
∫ τ
0
Kh(Vi − v)
{
Zi − Sn10(t, θ̂(v))
Sn00(t, θ̂(v))
}
dΛi(t)− 12µ2h
2Σ(v)β′′(v)‖∞.
Similarly to (26) and (27), the first term on the right-hand side of the above equation is bounded
by Op
({
log(1/h)
nh
}1/2
h2 +
{
log(1/h)
nh
})
, and the second term on the right-hand side of the above
equation is bounded by Op
({
log(1/h)
nh
}1/2
h2 + h4
)
. Hence we have
‖Bn(v)− 12µ2h
2Σ(v)β′′(v)‖∞ ≤ p
({
log(1/h)
nh
}1/2
h2 +
{
log(1/h)
nh
}
+ h4
)
Finally, we consider Π̂n(v). According to lemma 3, we have
‖Π̂n(v)− ν0Σ(v)‖∞
≤ ‖Π̂n(v)− 1
nh
n∑
i=1
∫ τ
0
K2h(Vi − v)
{
Zi − Sn10(t, θ(v))
Sn00(t, θ(v))
}⊗2
dNi(t)‖∞
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+‖ 1
nh
n∑
i=1
∫ τ
0
K2h(Vi − v)
{
Zi − Sn10(t, θ(v))
Sn00(t, θ(v))
}⊗2
dNi(t)− ν0Σ(v)‖∞
= Op
({
log(1/h)
nh
}1/2
+ h2
)
.
Therefore, since nh5 = O(1), we have
√
nh‖b̂ias(β̂(v))− 1
2
µ2h
2β′′(v)‖∞ = Op
(
{log(1/h)}1/2 h2
)
,
and ‖Σ̂−1(v)− Σ−1(v)‖∞ = Op
({
log(1/h)
nh
}1/2)
.
Hence, Theorem 3 follows.
Proof of Theorem 4. Note that
ψ̂(p)− ψ0(p)− b̂ias(ψ̂(p))
= β̂(pip)− β0(pip)− b̂ias(β̂(pip))
= β̂(pip)− β̂(pip) + β̂(pip)− β0(pip)− b̂ias(β̂(pip))
= β̂
′
(pip)(pip − pip) + op(|pip − pip|) + {β̂(pip)− β0(pip)− b̂ias(β̂(pip))}.
Thus, it’s sufficient to prove
sup
0≤p≤1
|(log(1/h))1/2
√
nh
{
β̂
′
(pip)(pip − pip) + op(|pip − pip|)
}
| = op(1). (29)
We first prove sup
0≤p≤1
|pip − pip| = Op
(
n−1/2
)
. According to the definition of pip, we have
F̂v(pip−) ≤ p ≤ F̂v(pip), and sup
0≤p≤1
|F̂v(pip−) ≤ p ≤ F̂v(pip)| = op(n−1/2).
Hence, it follows from sup
x
|F̂v(x)− Fv(x)| = op
(
n−1/2
)
that
sup
0≤p≤1
|Fv(pip)− Fv(pip)| ≤ sup
0≤p≤1
|Fv(pip)− F̂v(pip)|+ sup
0≤p≤1
|F̂v(pip)− p|
= Op
(
n−1/2
)
+ op(n−1/2) = Op
(
n−1/2
)
.
Note that
Fv(pip)− Fv(pip) = fv(pip)(pip − pip) + op(|pip − pip|).
29
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Thus, sup
0≤p≤1
|pip − pip| = Op
(
n−1/2
)
, which yields that
sup
0≤p≤1
|(log(1/h))1/2
√
nh
{
β̂
′
(pip)(pip − pip) + op(|pip − pip|)
}
|
= Op
(
{h log(1/h)}1/2
)
= op(1).
Theorem 4 follows.
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Figure 1: Different BATE curves with different sensitive subsets
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Figure 2: Comparing between a ”strong” predictive marker and a ”weak” predictive marker.
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Figure 3: The BATE curves for different treatment arms: The solid, dashed and dotted curves are
the BATE curves for Treatment 1,2 and 3, respectively.
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Figure 4: Estimated results of the case with censoring rate CR = 20%. For each figure, solid and
dashed lines are the true and estimated curves, respectively. Dotted and dash-dotted lines are 95%
confidence limits and 95% confidence bands, respectively.
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Figure 5: Estimated results of the case with censoring rate CR = 40%. For each figure, solid and
dashed lines are the true and estimated curves, respectively. Dotted and dash-dotted lines are 95%
confidence limits and 95% confidence bands, respectively.
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Figure 6: Estimation of the BATE curves: (A) is for the BATE curve versus c − myc , (B) is
for the modified BATE curve versus p. Solid, dashed and dotted lines are estimated curves, 95%
confidence limits and 95% confidence band, respectively.
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Figure 7: Estimation of the BATE curves: (A) is for the BATE curve versus c − myc , (B) is
for the modified BATE curve versus p. Solid, dashed and dotted lines are estimated curves, 95%
confidence limits and 95% confidence band, respectively.
38
http://biostats.bepress.com/uwbiostat/paper376
List of Tables
1 Estimation results of the BATE curves . . . . . . . . . . . . . . . . . . . . . . . . . . 40
2 Simulation results of the hypothesis test . . . . . . . . . . . . . . . . . . . . . . . . . 41
39
Hosted by The Berkeley Electronic Press
Table 1: Estimation results of the BATE curves
ψ1(p) ψ2(p)
CR p Bias SD SE CP Bias SD SE CP
20% 0.2 0.0374 0.3116 0.2995 0.94 -0.0165 0.3145 0.2894 0.93
0.4 -0.0103 0.2416 0.2279 0.92 -0.0265 0.2321 0.2190 0.94
0.6 -0.0343 0.2319 0.2228 0.94 0.0418 0.2350 0.2159 0.93
0.8 -0.0339 0.2983 0.2855 0.91 0.1207 0.3264 0.2937 0.93
40% 0.2 0.0354 0.3348 0.3357 0.97 -0.0287 0.3175 0.3232 0.91
0.4 -0.0143 0.2604 0.2545 0.90 -0.0422 0.2589 0.2439 0.94
0.6 -0.0400 0.2572 0.2443 0.92 0.0286 0.2649 0.2384 0.92
0.8 -0.0394 0.3303 0.3083 0.92 0.1268 0.3477 0.3216 0.95
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Table 2: Percentage of rejecting null hypothesis given significant level α∗ = 0.05 and censoring
rate 20% based on 500 simulations
β1(v) ≡ −1, α∗ = 0.01 β1(v) ≡ −1, α∗ = 0.05
β2(v) 2 sin(3v) − exp(v) 0.5 2 sin(3v) − exp(v) 0.5
Type I errors 0.014 0.008 0.010 0.066 0.050 0.056
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